Utilizing a measured approach can increase the probability for identifying search criteria that fulfill a company’s strategy.
Ranan Lachman
Advertisement
Articles by Ranan Lachman
Out-licensing has become a crucial part of most biotech companies' business strategies.
Companies should dig in a more attractive mine where very few other companies are looking.
Advertisement
Latest Updated Articles
Private Industry's Most EligibleOctober 1st 2004
The Art and Process of Successful In-LicensingJune 1st 2005
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
2
Zai Lab’s Long-Acting Atopic Dermatitis Bispecific Points to Every-12-Week Dosin
3
What 3 Principles Guide Merck's Biologics and ADC Capacity Placement?
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5